Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of 36 patients with systemic sclerosis

From: Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop

Characteristic n(%)
Organ involvement  
   Joint contractures 16 (44%)
   Esophageal hypomotility 24 (67%)
   Cardiac involvement 1 (3%)
   Renal involvement 1 (3%)
   Interstitial lung disease 22 (62%)
   Pulmonary arterial hypertension 1 (3%)
   Digital pitting scars 18 (50%)
Systemic sclerosis-related autoantibodiesa  
   Anti-topoisomerase I 16 (44%)
   Anticentromere 7 (19%)
   Anti-RNA polymerase III 2 (6%)
   Anti-U1 ribonucleoprotein 7 (19%)
   Anti-Th/To 2 (6%)
   Not identified 5 (14%)
Medications reported when blood samples collected  
   Prednisolone (≤10 mg/day) 11 (31%)
   Cyclophosphamide 1 (3%)
   Nonsteroidal anti-inflammatory drug 5 (14%)
   D-Penicillamine 3 (8%)
   Oral prostanoid 19 (53%)
   Calcium channel blocker 2 (6%)
   Statin 6 (17%)
   Anti-platelet aggregation 6 (17%)
   Antacid 12 (33%)
  1. aThree patients had two systemic sclerosis-related autoantibodies: one patient with anti-topoisomerase I and anticentromere; one patient with anti-topoisomerase I and anti-U1 ribonucleoprotein; and one patient with anticentromere and anti-U1 ribonucleoprotein.